PFS for all patients and for patients with CR. (A) Median PFS was 10.5 months (range, 2.6+ to 22.3+ months) in all efficacy-evaluable patients (N = 26). (B) Median PFS was 11.8 months (range, 4.1 to 22.3+ months) in patients with CR (n = 19). Censored patients are indicated by open circles (○).